A Nasal Treatment for COVID-19

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to test an investigational new inhaled medication called Optate.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University
• Treatments: Glycine

Criteria

Inclusion Criteria: Subjects, 18 and above, with mild COVID-19 upper respiratory tract infection symptoms

• positive rapid COVID-19 test

• Ordinal Scale for Clinical Improvement < 3 (OSCI, Appendix 2) and/or

• Fever > 100 degree F and/or

• Nasal congestion

Exclusion Criteria:

• FEV1 (Forced Exhaled Volume) < 55% predicted on the day of study procedures

• OSCI ≥ 3 (Objective Structured Clinical Exam)

• Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication